Nature Cancer : Impact Factor & More
eISSN: 2662-1347pISSN: 2662-1347
Share this on:
Key Metrics
CiteScore 
12.2
Impact Factor
20 - 25
Scite Index
0.94 5-Year SI
SJR
Q4Oncology
SNIP
2.84
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Nature Cancer
Nature Cancer Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | NATURE PORTFOLIO |
| Language | English |
| Frequency | Monthly |
| General Details |
View less
Planning to publish in Nature Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Nature Cancer
Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance.
- 19 May 2026
- Nature cancer
Immunological outcomes of a bespoke DNA cancer vaccine in glioblastoma.
- 18 May 2026
- Nature cancer
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.
- 15 May 2026
- Nature cancer
CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8+ T cells.
- 15 May 2026
- Nature cancer
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
- 13 May 2026
- Nature cancer
Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.
- 12 May 2026
- Nature cancer
Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance.
- 19 May 2026
- Nature cancer
Immunological outcomes of a bespoke DNA cancer vaccine in glioblastoma.
- 18 May 2026
- Nature cancer
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.
- 15 May 2026
- Nature cancer
CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8+ T cells.
- 15 May 2026
- Nature cancer
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
- 13 May 2026
- Nature cancer
Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.
- 12 May 2026
- Nature cancer
FAQs on Nature Cancer
How long has Nature Cancer been actively publishing? 
What is the publishing frequency of Nature Cancer?
How many articles did Nature Cancer publish last year?
What is the eISSN & pISSN for Nature Cancer?
What is Citescore for Nature Cancer?
What is SNIP score for Nature Cancer?
What is the SJR for Nature Cancer?
Who is the publisher of Nature Cancer?
